Last Day of the Subscription Period in Spago Nanomedical’s Rights Issue

NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG-KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION TO ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN SPAGO NANOMEDICAL AB IN ANY JURISDICTION.

LUND, SE / ACCESSWIRE / November 23, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Today, November 23, 2023, is the last day of the subscription period in Spago Nanomedical AB (publ)'s ("Spago Nanomedical" or the "Company") fully secured rights issue of units of approximately SEK 30.6 million, before transaction costs (the "Rights Issue"), which was proposed by the Board of Directors on October 5, 2023, and resolved by the Extraordinary General Meeting held on October 31, 2023.

For complete information about the Rights Issue, please refer to the prospectus (" Prospectus ") established by the board of directors on the occasion of the Rights Issue and which was published on November, 2023. The Prospectus is available on the Company's, Hagberg & Aneborn Fondkommission AB's and Redeye AB's respective websites ( www.spagonanomedical.se , www.hagberganeborn.se , www.redeye.se ). The Prospectus is also available on the Swedish Financial Supervisory Authority's website ( www.fi.se ). Subscription forms are available on the Company's, Hagberg & Aneborn Fondkommission AB's, and Redeye AB's respective websites.

Timetable for the Rights Issue

November 9 - 23, 2023	Subscription period
November 9, 2023 - Until the Rights Issue is registered with the Swedish Companies Registration Office	Trading in paid subscribed units (Sw. "BTU")
Around November 27, 2023	Estimated publication of the outcome in the Rights Issue

Advisors

Redeye AB acts as financial advisor, and Advokatfirman Cederquist KB act as legal advisor to Spago Nanomedical in connection with the Rights Issue.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, [phone], [e-mail]

Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.